WeVote
Log In

Bill

Bill

SB 2855

RELATING TO OPIOID ANTAGONISTS.

2026 Regular Session Introduced by Stanley Chang and 3 co-sponsors

Hawaii bill to modify opioid antagonist access and distribution mechanisms; currently in committee review with public hearing scheduled for February 9, 2026.

The committee(s) on HHS has scheduled a public hearing on 02-09-26 1:05PM; Conference Room 225 & Videoconference.
#healthinsurance #healthinsurers #healthmaintenanceorganizations #mutualbenefitsocieties #opioidantagonists #prescriptiondrugcoverage
0
WeVote Research Nonpartisan
Bill Summary · SB 2855

Legislative bill overview

SB 2855 addresses opioid antagonist access and distribution in Hawaii, though the specific provisions are not detailed in the available information. The bill is currently in early legislative stages, having passed first reading and been referred to the Health and Human Services (HHS) and Consumer Protection and Commerce (CPN) committees for review.

Why is this important

Opioid antagonists like naloxone (Narcan) are critical emergency medications that reverse opioid overdoses and can save lives. Hawaii, like many states, has faced rising opioid-related deaths, making access to these medications a public health priority. Legislation in this area typically aims to expand availability, reduce barriers to distribution, or clarify legal protections for users and providers.

Potential points of contention

  • Cost and funding mechanisms - Whether the state, insurance companies, individuals, or prescribers bear costs for opioid antagonists
  • Distribution channels - Disagreement over whether pharmacies, emergency responders, community organizations, or other entities should distribute antagonists, and whether prescriptions are required
  • Legal liability protections - Questions about immunity for bystanders or medical professionals who administer opioid antagonists in emergency situations

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.